During the open label trial, 57.1% of roflumilast-treated participants achieved Investigator Global Assessment (IGA) of clear or almost clear at any time in study; the median duration of…
Regulatory submission for the expanded indication is supported by data from two recently completed 4-week Maximal Usage Systemic Exposure (MUSE) studies in children ages 2 to 11 years with…
Study met both co-primary endpoints and all secondary endpointsAt week eight, 67.3% of individuals treated with roflumilast foam achieved Scalp-Investigator Global Assessment (S-IGA)…
Roflumilast cream showed higher efficacy compared to vehicle in both Phase 3 studies on the primary efficacy endpoint of Investigator Global Assessment (IGA) success, with 40% of…
Study met its primary endpoint with 80% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared to 59% of patients treated with vehicle…
WESTLAKE VILLAGE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations…
WESTLAKE VILLAGE, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing…
Arcutis Cares provides ZORYVE™ (roflumilast) cream 0.3% at no cost for financially eligible individuals who are uninsured or have Medicaid or Medicare Part D prescription coverage and…